purged marrow cells to hematopoietic recovery by 
the normal stem cells. Differences will be 
analyzed by the students T test to determine if a 
statistically significant difference exists 
between the frequency by the two viruses after 
transplants . 
10.3 Stopping Rules: If three successive patients 
have treatment deaths due to failure to engraft, 
delayed hematopoietic recovery, or any treatment 
related cause, the trial will be stopped. 
10.4 Reporting requirements: All adverse outcomes 
will be reported to the RAC, the FDA, and the 
NCI . 
[402] 
Recombinant DNA Research, Volume 16 
